0001193125-26-220506.txt : 20260513 0001193125-26-220506.hdr.sgml : 20260513 20260513060513 ACCESSION NUMBER: 0001193125-26-220506 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260512 FILED AS OF DATE: 20260513 DATE AS OF CHANGE: 20260513 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Schreiber Taylor CENTRAL INDEX KEY: 0001601942 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39593 FILM NUMBER: 26970761 MAIL ADDRESS: STREET 1: 100 EUROPA DRIVE CITY: CHAPEL HILL STATE: NC ZIP: 27517 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Shattuck Labs, Inc. CENTRAL INDEX KEY: 0001680367 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 812575858 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 500 W. 5TH STREET CITY: AUSTIN STATE: TX ZIP: 78701 BUSINESS PHONE: 512-900-4690 MAIL ADDRESS: STREET 1: 500 W. 5TH STREET CITY: AUSTIN STATE: TX ZIP: 78701 4 1 ownership.xml 4 X0609 4 2026-05-12 0001680367 Shattuck Labs, Inc. STTK 0001601942 Schreiber Taylor false C/O SHATTUCK LABS, INC. 500 W. 5TH STREET, SUITE 1200 AUSTIN TX 78701 true true false false Chief Executive Officer false Common Stock 2026-05-12 4 A false 25610 1.0846 A 122222 D Common Stock 2610750 I By Houghton Capital Holdings, LLC Warrants (Right to Buy) 1.0846 2026-05-12 4 M false 25610 D Common Stock 25610 0 D On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 25,610 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 25,610 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677. The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly. /s/ Andrew R. Neill, Attorney-in-Fact for Taylor Schreiber 2026-05-13